Literature DB >> 32095979

Better outcomes for patients with gout.

Richard Day1,2, Amy Nguyen3,4, Garry Graham5,6, Eindra Aung3,5, Mathew Coleshill3,5, Sophie Stocker3,5.   

Abstract

Gout is increasing in prevalence despite effective pharmacotherapies. Barriers to effective management are largely educational deficiencies. Sufferers, usually men, need to understand more about gout, especially that maintaining serum urate below 0.36 mmol/L will eliminate recurrent attacks. Also, of great importance is appreciating that sub-optimal adherence to urate-lowering therapy (ULT) will result in a return of attacks. Prescribers also need to understand that acute attacks are likely to occur in the first few months of urate-lowering therapy (ULT), but these can be mitigated by commencing with a dose of ULT reflective of renal function and escalating the dose slowly, every 2-5 weeks until target serum urate is achieved. Prophylaxis against acute attacks over the initial 6 months period of ULT can be enhanced further with concomitant colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs).Gout is largely managed in primary care. Rates of adherence to ULT are 50% or less, worse than most other chronic illnesses. Efforts at educating primary care physicians to, firstly, manage gout effectively and, secondly, to educate their gout patients sufficiently have not been successful. Allied health practitioners, such as nurses, working with prescribers in primary care settings and given the mandate to educate and manage patients with gout, have been spectacularly effective. However, this approach is resource intensive. 'Personalised' eHealth interventions show promise as an alternative strategy, notably in improving adherence to ULT.Numerous applications for smart phones (apps) are now available to assist people with chronic health conditions. Their design needs to accommodate the barriers and enablers perceived by patients to maintaining adherence to prescribed therapies. Personalised feedback of serum urate may represent an important enabler of adherence to ULT in the case of gout.Harnessing mobile apps to support patients managing their chronic illnesses represents an important opportunity to enhance health outcomes. Rigorous, patient-centred and driven development is critical. These tools also require careful evaluation for effectiveness.

Entities:  

Keywords:  Adherence; Allopurinol; Barriers; Dose–response; Enablers; Gout

Mesh:

Substances:

Year:  2020        PMID: 32095979     DOI: 10.1007/s10787-020-00694-7

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  35 in total

1.  Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.

Authors:  Abhishek Abhishek; Wendy Jenkins; Jonathan La-Crette; Gwen Fernandes; Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

2.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

3.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

4.  Purine-rich foods, dairy and protein intake, and the risk of gout in men.

Authors:  Hyon K Choi; Karen Atkinson; Elizabeth W Karlson; Walter Willett; Gary Curhan
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

5.  The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years.

Authors:  Mohanad M Elfishawi; Nour Zleik; Zoran Kvrgic; Clement J Michet; Cynthia S Crowson; Eric L Matteson; Tim Bongartz
Journal:  J Rheumatol       Date:  2017-12-15       Impact factor: 4.666

6.  Gout Severity, Socioeconomic Status, and Work Absence: A Cross-Sectional Study in Primary Care.

Authors:  Zachary Bowen-Davies; Sara Muller; Christian D Mallen; Richard A Hayward; Edward Roddy
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-12       Impact factor: 4.794

7.  Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout.

Authors:  Caitlin Batt; Amanda J Phipps-Green; Michael A Black; Murray Cadzow; Marilyn E Merriman; Ruth Topless; Peter Gow; Andrew Harrison; John Highton; Peter Jones; Lisa Stamp; Nicola Dalbeth; Tony R Merriman
Journal:  Ann Rheum Dis       Date:  2013-09-11       Impact factor: 19.103

Review 8.  Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.

Authors:  Thomas Bardin; Pascal Richette
Journal:  BMC Med       Date:  2017-07-03       Impact factor: 8.775

9.  Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study.

Authors:  Allyce B Counsell; Amy D Nguyen; Melissa T Baysari; Diluk R W Kannangara; Andrew J McLachlan; Richard O Day
Journal:  BMC Fam Pract       Date:  2018-05-09       Impact factor: 2.497

10.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.

Authors:  Michael Doherty; Wendy Jenkins; Helen Richardson; Aliya Sarmanova; Abhishek Abhishek; Deborah Ashton; Christine Barclay; Sally Doherty; Lelia Duley; Rachael Hatton; Frances Rees; Matthew Stevenson; Weiya Zhang
Journal:  Lancet       Date:  2018-10-20       Impact factor: 79.321

View more
  4 in total

1.  Illness perception and treatment experience in patients with gout: a descriptive qualitative study.

Authors:  Qin Li; Ting Liu; Shan Zhang; Xiuxin Miao
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

Review 2.  Why Does Hyperuricemia Not Necessarily Induce Gout?

Authors:  Wei-Zheng Zhang
Journal:  Biomolecules       Date:  2021-02-14

3.  How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians?

Authors:  Sanja Zuzic Furlan; Doris Rusic; Josko Bozic; Mirjana Rumboldt; Zvonko Rumboldt; Marko Rada; Marion Tomicic
Journal:  Int J Environ Res Public Health       Date:  2021-01-30       Impact factor: 3.390

4.  Regulatory Role of miRNAs and lncRNAs in Gout.

Authors:  Jianlong Shu; Minhua Chen; Chunse Ya; Ruixia Yang; Fengzhen Li
Journal:  Comput Math Methods Med       Date:  2022-06-29       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.